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My colleagues and I read with great interest the recent article
by Ji and colleagues reporting the effect of vitamin E on serum
aminotransferase levels in patients with nonalcoholic fatty liver
disease (NAFLD), nonalcoholic steatohepatitis (NASH), and
chronic hepatitis C, evaluated by meta-analysis [1]. NAFLD is
increasingly recognized as a common cause of chronic liver dis-
eases in association with the current epidemic prevalence of
obesity and diabetes mellitus in the general population. NAFLD
is now regarded as a manifestation of metabolic syndrome and
the link between obesity, diabetes mellitus, cardiovascular dis-
ease and NAFLD is likely to reﬂect shared pathogenic factors.
The spectrum of NAFLD ranges from simple hepatic steatosis
without associated necroinﬂammatory changes or ﬁbrosis to
NASH, which is characterized by necroinﬂammation, cytopathic
changes in hepatocytes, such as ballooning degeneration and
Mallory-Denk body, and various degrees of ﬁbrosis [2,3]. Several
studies have been aimed at discovering pharmacologic treat-
ments for NAFLD/NASH; however, despite the clinical impor-
tance, unfortunately, there is still a lack of consensus for
pharmacologic treatment of the diseases. Oxidative stress is
considered to be one of the main players in the development
and progression of NAFLD/NASH [4–6], and vitamin E is known
as a free radical scavenger, acting on TGF-b1, peroxisome
proliferator-activated receptors, and apoptosis regulating genes
[7,8]. Ji and colleagues tried to evaluate the efﬁcacy of vitamin E
on NAFLD/NASH by meta-analyzing previously published data
through June 2013. They found that vitamin E has a preferred ef-
fect on NAFLD/NASH as well as chronic hepatitis C by improving
serumaminotranseferase levels.We initially reported the efﬁcacy
of vitamin E in adult patients with NASH [9]. We enrolled 12 pa-
tients with NASH and 10 with NAFLD. All patients were given di-
etary instruction for 6 mo, and thereafter vitamin E (300 mg/d;
100 mg is equivalent to 100 IU) was given to only patients with
NASH for 1 y. In consequence, plasma aminotranseferase levels
were improved by diet in patients with NAFLD but not those
with NASH, and then we gave vitamin E to only patients with
NASH because serum biochemical markers in patients with
NAFLD had been already improved by diet without medications.
We greatly appreciate Ji and colleagues for referencing and
including our data in their analysis; however, we did not examine
the effect of vitamin E on NAFLD patients. We are concerned that
the authors misread our data because they included our data in
meta-analysis of vitamin E’s effect on NAFLD though we did not
give vitamin E to these patients. Moreover, as far as we know, still0899-9007/ 2015 Elsevier Inc. Open access under CC BY-NC-ND license.several randomized controlled trials, which have higher evidence
levels comparedwith our previous pilot study, do exist, but Ji and
colleagues did not included these trials in their meta-analysis.
For example, a Pioglitazone versus Vitamin E versus Placebo
for the Treatment of Nondiabetic Patients with Nonalcoholic
Steatohepatitis study dealt with a large population of NASH pa-
tients and observed them for 96 wks to evaluate the efﬁcacy of
vitamin E on NASH [10], and a Treatment of NAFLD in Children
study also examined vitamin E’s effect in child NASH patients
[11]. Because we really cannot understand why Ji and colleagues
excluded the data of these large randomized controlled trials,
we strongly recommend Ji and colleagues reanalyze the efﬁcacy
of vitamin E on NAFLD/NASH by including large randomized
controlled trial data and excluding our reported data fromNAFLD
meta-analysis. Otherwise, the readers of “Nutrition” maymisun-
derstand their articles.References
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aminotransferase levels in
NAFLD/NASH patientsNonalcoholic fatty liver disease (NAFLD) is one of the most
prevalent diseases worldwide. In view of the widely accepted
role of oxidative stress in the pathogenesis of NAFLD, many anti-
oxidants have been widely used to treat the disease [1,2]. In
recent years, the therapeutic effects of vitamin E for NAFLD
have been widely studied. With the aim to evaluate the thera-
peutic efﬁcacy, we performed a meta-analysis on the effects of
vitamin E supplement in lowering the aspartate transaminase
(AST) and alanine transaminase (ALT) levels in patients with
NAFLD and nonalcoholic steatohepatitis (NASH) [3]. I appreciate
Yoneda et al. for their interest in our study [4] and would like to
provide more details about the reference selection criteria of our
meta-analysis. Yoneda et al. discussed that several recent high-
quality studies reporting the effects of vitamin E supplement
on NASH were not included in our meta-analysis [5,6]. We
certainly reviewed these studies during the data collection; how-
ever, they could not be included in our meta-analysis mainly for
two reasons.
First, during the study selection process, we required that
included studies must provide the exact mean and SD of the
baseline (before treatment) and endline (after treatment) ALT
and AST levels. However, there is lack of exact endline SD (after
treatment) of ALT and AST levels in PIVENS (Pioglitazone or
Vitamin E for NASH Study), which investigated the efﬁcacy of
vitamin E therapy on patients with NASH for 96 wk [5]. Similarly,
the TONIC (Treatment of NAFLD in Children) trial, which investi-
gated the efﬁcacy of vitamin E therapy for patients with pediatricNAFLD, did not provide endline SDs of ALT and AST levels [6].
Because SD is an important parameter to affect results, these
studies were not included in our meta-analysis to ensure accu-
racy. Second, ALT and AST levels were reported in two sets of
units in relative studies, U/L and IU/L, whereas the two units
cannot be transferred and thus the studies in different units
could not be divided in one group to perform meta-analysis,
which further limits the number of included studies. Addition-
ally, as a subtype of NAFLD, nonalcoholic fatty liver also can
lead to ﬁbrosis progression in patients, as suggested by emerging
studies. Thus, the data in the paper by Hasegawa et al. was
included in the NAFLD analysis, although exclusion of the data
would not inﬂuence the conclusion [7].
There is only limited number of eligible studies that can be
included in the meta-analysis at present. With more published
studies providing detailed results, a more comprehensive
conclusion can be drawn on the therapeutic effect of vitamin E
on NAFLD and NASH in future.References
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